Significance of NUDT15 gene in individualized treatment with 6-mercaptopurine in children with acute lymphoblastic leukemia.
- Author:
Jing HE
1
;
Ling LIU
Author Information
1. Department of Hematology and Oncology, Dalian Women and Children's Medical Center, Dalian, Liaoning 116000, China. liuling63@sina.com.
- Publication Type:Journal Article
- MeSH:
Antimetabolites, Antineoplastic;
Child;
Humans;
Mercaptopurine;
Methyltransferases;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Pyrophosphatases;
genetics
- From:
Chinese Journal of Contemporary Pediatrics
2019;21(1):100-104
- CountryChina
- Language:Chinese
-
Abstract:
As an important drug during maintenance treatment of acute lymphoblastic leukemia (ALL), 6-mercaptopurine (6-MP) has several side effects, including hepatotoxicity and bone marrow suppression. Since its tolerability varies from person to person, 6-MP treatment should be individualized. The deficiency of thiopurine methyltransferase (TPMT) enzyme activity is associated with 6-MP intolerance. There is a lower frequency of mutation in TPMT alleles among Asian patients. Recent studies have shown that in ALL patients with NUDT15 gene mutation, the maximum tolerated dose of 6-MP is lower than the conventional dose. The article reviews the significance of NUDT15 gene in individualized treatment with 6-MP in children with ALL.
